Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

On April 8, 2026 Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, reported that it has raised $5 million in additional funds for its Series B financing from new investor Hatteras Venture Partners. As part of the financing, Hatteras partner Kseniya Simpson, Ph.D., will join the Company’s board of directors and Hatteras general partner Christy Shaffer, Ph.D., will join as a board observer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are encouraged by Hatteras’s strong enthusiasm for our CDK2 program and their support in advancing INX-315 toward meaningful clinical outcomes," said Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder of Incyclix Bio. "Additionally, we’re pleased to welcome Kseniya and Christy to our board and look forward to working with them during this pivotal time of growth for Incyclix."

The additional funds will support of the clinical development of the Company’s lead compound INX-315, a novel, potent and selective CDK2 inhibitor, for the treatment of advanced and metastatic breast and ovarian cancer. Hatteras joins other top-tier investors who participated in the Series B round, including Boxer Capital, RA Capital Management, Eshelman Ventures, Eli Lilly and Company, Pharmacosmos and Cape Fear BioCapital.

"CDK2 inhibition represents an exciting opportunity to address unmet need that remains in breast and ovarian cancer treatment," said Kseniya Simpson, Ph.D. "We believe in Incyclix’s highly experienced team and their capabilities to bring a best-in-class treatment option to patients with advanced and resistant cancer."

The Phase 1/2 open-label, dose-escalation, combination and dose-expansion clinical trial of INX-315 is ongoing. More information on the INX-315-10 trial can be found at clinicaltrials.gov (NCT05735080).

(Press release, Incyclix Bio, APR 8, 2026, View Source [SID1234664257])